Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pituitary Neoplasms 3Nelson Syndrome 2Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Meningioma 1Carcinoma, Intraductal, Noninfiltrating 1Adrenocortical Hyperfunction 1ACTH Syndrome, Ectopic 1

Interventions

Specimen Handling 3Mastectomy, Segmental 2polyphenon E 1perflutren 1pasireotide 1palbociclib 1fezolinetant 1abemaciclib 1Yoga 1UAB 30 1Tea 1Tamoxifen 1Surgical Procedures, Operative 1Sugars 1Radiotherapy 1Radiation 1Naltrexone 1Mifepristone 1Lapatinib 1Hypericum extract LI 160 1Genotype 1Gefitinib 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Intraductal, Noninfiltrating × pasireotide × Clear all
NCT01372618 2017-12-27

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

NYU Langone Health

Phase 1/2 Terminated
9 enrolled 3 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡